rTG Omega-3: Why Molecular Form Determines Bioavailability
— A Neurologist's Guide

1. The Omega-3 Processing Problem

Omega-3 fatty acids occur naturally in marine oils in the triglyceride (TG) form, esterified to a glycerol backbone at the sn-1, sn-2, and sn-3 positions. In their native state, however, EPA and DHA concentrations in fish oil are relatively modest — typically 25–30% of total fatty acids — insufficient to deliver clinically relevant doses within a practical daily capsule volume.

The nutraceutical industry addresses this concentration problem through molecular distillation: fish oil is transesterified with ethanol, liberating the fatty acids as ethyl esters (EE) and enabling vacuum distillation to concentrate EPA and DHA to 60–90% of total fatty acids. The EE form is the most widely distributed omega-3 supplement format globally, primarily because of its manufacturing simplicity and lower production cost relative to alternative forms. What this processing step costs in bioavailability terms is the central clinical question this article addresses.

2. Ethyl Ester (EE) Form: The Bioavailability Cost of Cheap Manufacturing

The EE form presents a fundamental gastrointestinal absorption challenge: ethyl esters do not occur in mammalian physiology, and the human digestive system is consequently ill-equipped to process them efficiently. Pancreatic lipase — the principal enzyme mediating intestinal fatty acid absorption — demonstrates substantially lower catalytic affinity for ethyl ester substrates compared to triglyceride substrates. In vitro kinetic analyses indicate that pancreatic lipase hydrolyzes TG substrates approximately 50-fold faster than equivalent EE substrates under physiological conditions.

The clinical consequence is reduced and highly variable absorption. EE-form omega-3 is strongly fat-dependent: studies demonstrate that EE omega-3 taken in a fasted state achieves plasma EPA+DHA increments only 20–30% of those achieved when taken with a high-fat meal. This fat-dependency creates substantial real-world variability in the plasma omega-3 index achieved by patients taking nominally equivalent doses — a variable that is rarely communicated to consumers purchasing EE-form products.

3. Natural TG Form: Better Absorption, Lower Concentration

Natural TG-form fish oils — in which EPA and DHA remain esterified to a glycerol backbone in their native configuration — are processed by pancreatic lipase via the same enzymatic pathway as dietary fat, achieving substantially superior absorption compared to EE forms. Meta-analytic data suggest that TG-form omega-3 increases the plasma omega-3 index approximately 23–50% more effectively than equivalent EE doses.

The practical limitation of natural TG forms is concentration: because the re-esterification step required to achieve high EPA+DHA percentages is absent, natural TG products typically contain only 30–50% EPA+DHA, necessitating larger or more numerous capsules to achieve therapeutic doses. This profile — high absorption efficiency but low concentration — is the inverse of the EE form. Selecting between them involves an undesirable trade-off that the rTG form resolves.

4. Re-Esterified TG (rTG) Form: Resolving the Trade-off

The rTG form addresses both limitations through an additional manufacturing step: EE-concentrated omega-3 is enzymatically re-esterified back onto a glycerol backbone, reconstituting the triglyceride structure while retaining high EPA+DHA concentrations (typically 70–90% of total fatty acids). The resulting molecule combines the high EPA+DHA density of the EE form with the physiologically compatible absorption kinetics of the natural TG form.

The Definitive Bioavailability Evidence

Dyerberg and colleagues (2010) published the landmark comparative bioavailability trial in Prostaglandins, Leukotrienes and Essential Fatty Acids. In a randomized crossover design of 72 healthy subjects, plasma EPA+DHA area-under-the-curve (AUC) values were measured following single doses of EE, natural TG, and rTG-form omega-3. The results established a clear hierarchy:

▲ Relative plasma EPA+DHA AUC vs. EE form (Dyerberg et al., 2010)

Neubronner et al. (2011) confirmed and extended these findings in a 26-week parallel-group trial of 150 subjects, demonstrating significantly superior omega-3 index elevation — the erythrocyte membrane EPA+DHA percentage — with rTG versus EE supplementation over a clinically meaningful timeframe. The omega-3 index is the preferred endpoint for evaluating supplementation efficacy because erythrocyte membrane composition reflects cumulative omega-3 status over the preceding 8–12 weeks (the erythrocyte lifespan), providing a time-integrated biomarker that correlates with tissue EPA+DHA levels far more reliably than single-timepoint plasma measurements.

5. The Omega-3 Index: Why Target Tissue Concentration Matters

The omega-3 index — defined as the percentage of EPA+DHA in erythrocyte membrane phospholipids — has emerged as a significant cardiovascular and neurological risk biomarker. Harris WS (2007) proposed the omega-3 index as an independent cardiovascular risk factor, with an index ≥8% associated with the lowest risk tier in epidemiological cohorts, compared to the 4–5% range typical of Western populations.

For neurological applications, the erythrocyte omega-3 index provides a practical proxy for the brain's DHA status — directly relevant to the neuronal membrane composition changes that underpin the cognitive effects of long-term omega-3 supplementation. The bioavailability advantage of rTG over EE forms translates directly into greater omega-3 index elevation per unit dose, which is to say: greater biological effect per capsule consumed.

6. DHA and the Neurological Case for Omega-3

DHA constitutes approximately 15–20% of total fatty acids in brain gray matter and is the dominant structural fatty acid in both neuronal plasma membranes and synaptic vesicle membranes. Its unique molecular geometry — six double bonds producing a highly flexible polyunsaturated chain — confers exceptional membrane fluidity, enabling the rapid lateral diffusion of ion channels, receptor complexes, and signal transduction proteins that is prerequisite for efficient synaptic transmission.

The neurobiological consequences of DHA deficiency are well-documented in animal models: reduced synaptic spine density, impaired hippocampal neurogenesis, suppressed BDNF expression, and deficits on spatial memory tasks. Human epidemiological data associate lower plasma and erythrocyte DHA with accelerated cognitive decline and greater dementia risk, though causality remains an active research question. Because the brain's capacity for endogenous DHA synthesis from alpha-linolenic acid (ALA) is severely limited — conversion efficiency below 1% in most adults — adequate dietary or supplemental DHA intake is a prerequisite for maintaining neuronal membrane DHA content across the lifespan.

7. EPA and Neuroinflammation Resolution

EPA's neurological relevance operates primarily through the resolution of neuroinflammation. EPA competes with arachidonic acid (AA) for both cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) enzymes, reducing the production of pro-inflammatory eicosanoids — prostaglandin E2 (PGE2) and leukotriene B4 (LTB4) — that contribute to chronic neuroinflammatory signaling. Beyond competitive inhibition, EPA serves as the direct precursor for E-series resolvins (RvE1, RvE2) — specialized pro-resolving mediators (SPMs) that actively terminate inflammatory responses in neural tissue, in contrast to conventional anti-inflammatory agents that merely inhibit the initiation of inflammation.

Elevated AA:EPA ratios — a characteristic feature of Western dietary patterns — favor pro-inflammatory eicosanoid production and have been associated with increased neuroinflammatory markers in cross-sectional epidemiological studies. Calder (2015) provides a comprehensive mechanistic review of how marine omega-3 fatty acids modulate inflammatory processes at the cellular and molecular level. rTG-form EPA supplementation, by achieving higher plasma EPA concentrations per dose, more effectively shifts the AA:EPA ratio toward pro-resolving signaling — a clinically relevant distinction when supplementing for neuroinflammatory applications.

8. Selection Criteria for rTG Omega-3